---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-100211"
form_type: "8-K/A"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-08-23T23:59:59+00:00"
generated_at: "2026-05-31T07:50:27.208275+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics discloses CEO separation terms: $450K payment, RSU vesting/forfeiture

## Summary
- Rachelle Jacques stepped down as President and CEO effective May 1, 2024.
- Separation agreement on Aug 19, 2024 provides $450K lump sum payment contingent on merger close or by Dec 2, 2024.
- Vesting of RSUs representing 276M ordinary shares; forfeiture of RSUs representing 482.25M ordinary shares.
- Payment condition tied to anticipated merger with Peak Bio, Inc.

## SEC filing metadata
- accession: 0000950170-24-100211
- form_type: 8-K/A
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-08-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024100211/0000950170-24-100211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024100211/aktx-20240425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-100211
- JSON: https://secwatch.observer/filing/0000950170-24-100211.json
- Plain text: https://secwatch.observer/filing/0000950170-24-100211.txt

## Key facts
- Executive change
  Rachelle Jacques departed as President and Chief Executive Officer at Akari Therapeutics Plc.
  - Action: stepped down
  - Role: President and Chief Executive Officer
  source text: Rachelle Jacques stepped down as the President and Chief Executive Officer of the Company, effective May 1, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000095017024100211/0000950170-24-100211-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.